Akihiko Soyama, Susumu Eguchi, Hiroto Egawa – 24 June 2016 – As of December 31, 2014, 7937 liver transplants (7673 living donor transplants and 264 deceased donor liver transplantations [DDLTs; 261 from heart‐beating donors and 3 from non–heart‐beating donors]) have been performed in 67 institutions in Japan. The revised Organ Transplant Law in Japan came into effect in July 2010, which allows organ procurement from brain‐dead individuals, including children, with family consent if the patient had not previously refused organ donation.

Vishwadeep Ahluwalia, James B. Wade, Melanie B. White, HoChong S. Gilles, Douglas M. Heuman, Michael Fuchs, Edith A. Gavis, Andrew Fagan, Felicia Tinsley, Dinesh Ganapathy, Leroy R. Thacker, Richard K. Sterling, R. Todd Stravitz, Puneet Puri, Arun J. Sanyal, Muhammad S. Siddiqui, Scott Matherly, Velimir Luketic, Joel Steinberg, F. Gerard Moeller, Jasmohan S. Bajaj – 24 June 2016 – The functional basis of cognitive and quality of life changes after liver transplant is unclear.

Markus Selzner, Nicolas Goldaracena, Juan Echeverri, Johan M. Kaths, Ivan Linares, Nazia Selzner, Cyril Serrick, Max Marquez, Gonzalo Sapisochin, Eberhard L. Renner, Mamatha Bhat, Ian D. McGilvray, Leslie Lilly, Paul D. Greig, Cynthia Tsien, Mark S. Cattral, Anand Ghanekar, David R. Grant – 24 June 2016 – The European trial investigating normothermic ex vivo liver perfusion (NEVLP) as a preservation technique for liver transplantation (LT) uses gelofusine, a non–US Food and Drug Administration–approved, bovine‐derived, gelatin‐based perfusion solution.

24 June 2016

24 June 2016

24 June 2016

Takanobu Hara, Akihiko Soyama, Masaaki Hidaka, Amane Kitasato, Shinichiro Ono, Koji Natsuda, Tota Kugiyama, Hajime Imamura, Satomi Okada, Zhassulan Baimakhanov, Tamotsu Kuroki, Susumu Eguchi – 24 June 2016 – We retrospectively analyzed the causes, risk factors, and impact of early relaparotomy after adult‐to‐adult living donor liver transplantation (LDLT) on the posttransplant outcome. Adult recipients who underwent initial LDLT at our institution between August 1997 and August 2015 (n = 196) were included. Any patients who required early retransplantation were excluded.

Mikel Gastaca, Mikel Guerra, Patricia Ruiz, Alberto Ventoso, Andrés Valdivieso, Jorge Ortiz de Urbina – 23 June 2016

Ki Tae Suk, Jung‐Hwan Yoon, Moon Young Kim, Chang Wook Kim, Ja Kyung Kim, Hana Park, Seong Gyu Hwang, Dong Joon Kim, Byung Seok Lee, Sae Hwan Lee, Hong Soo Kim, Jae Young Jang, Chang‐Hyeong Lee, Byung Seok Kim, Yoon Ok Jang, Mee Yon Cho, Eun Sun Jung, Yong Man Kim, Si Hyun Bae, Soon Koo Baik – 23 June 2016 – Bone marrow‐derived mesenchymal stem cell (BM‐MSC) transplantation has been suggested as an effective therapy for liver cirrhosis. The efficacy and safety of autologous BM‐MSC transplantation in the treatment of alcoholic cirrhosis were investigated.

Erin K. Spengler, David E. Kleiner, Robert J. Fontana – 23 June 2016 – Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation. Side effects of this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treated patients. Mild abnormalities in liver biochemistries were reported with vemurafenib use in 30% of subjects, 11% developed severe laboratory abnormalities, and acute liver failure has been reported (Table ).